Listing & Compliance Notices

SolarMax Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 3, 2026, SolarMax Technology, Inc. (the “Company”) received a notice from The Nasdaq Stock Market that the Company does not meet Nasdaq’s continued listing requirement of Rule 5550(a)(2) that the Company maintain a minimum bid price of $1 per share. The Nasdaq rules provide that the Company has a compliance period of 180 calendar days to regain compliance. This period expires on August 31. 2026. To become compliant, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive business days. In the event the Company does not regain compliance”

OSR Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 5, 2026, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company’s common stock had fallen below the required”

CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“f The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares of common stock on The Nasdaq Capital Market. The Company has 180 days, or until August 31, 2026, to regain c”

CIMG Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(2), 5250(c)(1), 5550(b)(1), 5620(a)).

“March 4, 2026, CIMG Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common stock, par value $0.00001 per share (the “Common Stock”) from The Nasdaq Stock Market due to the Company’s failures to comply with Nasdaq Listing Rules 5550(a)(2), 5250(c)(1), 5550(b)(1), and 5620(a). Trading in the Company’s Common Stock was suspended at the open of trading on March 6, 2026. The Company has 15 calendar days from the date of the Panel’s decision to request that the Nasdaq Listing”

Longeveron Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(2), 5605(c)(4)).

“March 4, 2026 Longeveron Inc. (the “Company”) notified Nasdaq that, as a result of the resignation of Mr. Richard Kender as a member of the Board of Directors (the “Board”) of the Company and as chairman of the Audit Committee and the audit committee financial expert, as described below, the Company temporarily was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be composed of at least three independent directors and that at least one member qualifies as an audit committee financial expert. On March 4, 2026, the Compan”

Trailblazer Merger Corp I received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

“March 3, 2026,Trailblazer Merger Corporation I (the “ Company ”) received a letter from Nasdaq (the “ Notice ”) which notified the Company that, for 30 consecutive business days, the Company’s market value of publicly held shares (“ MVPHS ”) was below the $15,000,000 threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(C) (the “ MVPHS Rule ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until August 31, 2026 (the “ MVPHS Compliance Period ”), to regain compliance with the MVPHS Rule. The Notice”

Iveda Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 6, 2026, Iveda Solutions, Inc., a Delaware corporation (the “Company”), received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s common stock failed to maintain a minimum bid price of $1 per share, based upon the closing bid price for the last 30 consecutive business days. Accordingly, the Company failed to comply with Rule 5550(a)(2) the Nasdaq Listing Rules (the “Rules”). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Rule 5810(c)(3)(A) provides the Company a”

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“March 5, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the bid price for the Company’s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Further, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)”

BEYOND MEAT, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 4, 2026, Beyond Meat, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (“the Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, an”

Nerdy Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“March 5, 2026, Nerdy Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing criteria under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A Common Stock was less than $1.00 over a consecutive 30 trading-day period. The Company notified the NYSE on March 6, 2026 that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. The Company can regain compliance at any time within the six-month period foll”

Offerpad Solutions Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“March 3, 2026, Offerpad Solutions Inc. (the “Company,” “we,” “us” or “our”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. On March 5, 2026, the Company notified the NYSE that it intends to cure the stock price deficiency and to return to compliance with the NYSE c”

Borealis Foods Inc. received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).

“March 2, 2026, Borealis Foods Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has reviewed and accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. As previously disclosed in the Company’s Current Report on Form 8-K filed on January 16, 2026, the Company was notified on January 12, 2026 that it was not in compliance with Nasdaq Li”

Traeger, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“March 5, 2026 , Traeger, Inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended March 4, 2026. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE. The Company intends to remain listed on the NYSE and is evaluati”

Artius II Acquisition Inc. received a nasdaq deficiency notice notice regarding other (rules 5452(a)(2)(A)).

“March 4, 2026, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s Listing Rule 5452(a)(2)(A) because the Company failed to maintain a minimum of 300 public holders of its units and Class A ordinary shares listed on The Nasdaq Global Market, as required under the Nasdaq continued listing standards for The Nasdaq Global Market. The Notice has no immediate effect on the listing of the Company’s securities on Nasdaq. Under Nasdaq Listing Rules, the Company has 45 calendar days to submit a plan”

Fly-E Group, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 27, 2026, Fly-E Group, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the listing qualifications staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “ Commission ”) its Form 10-Q for the period ended December 31, 2025 (the “ Form 10-Q ”). The Notice is a notification of deficiency, not of imminent delisting, and has no immediate effect on the listing or trading of the Company”

Vicarious Surgical Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).

“March 3, 2026, the New York Stock Exchange (the “NYSE”) notified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Commo”

Trinseo PLC received a nyse delisting notice notice regarding minimum bid price (rules 802.01C).

“ive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In addition, the Company also received written notice from the NYSE indicating that it was not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C because its average closing share price had fallen below $1.00 per share for 30 consecutive trading days. ​ As stated in the Notice, the NYSE will file a Form 25 with the SEC to delist the Company’s ordinary shares from the NYSE upon completion of applicable procedures. The delisting will be”

Trinseo PLC received a nyse delisting notice notice regarding other (rules 802.01B).

““Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE had determined to commence proceedings to delist the Company’s ordinary shares. As stated in the Notice, the NYSE reached its decision to delist the Company’s securities pursuant to Section 802.01B of the NYSE Listed Company Manual because the Company had fallen below the NYSE continued listing standard requiring listed companies to maintain an average market capitalization over a 30-trading day period of at least $15 million. The Notice also stated that trading in the Company’s ordina”

CVR PARTNERS, LP received a nyse noncompliance notice notice regarding audit committee (rules 303A.07(a), 303A.02, 10A-3).

“March 3, 2026, the Partnership received notice from the NYSE that it became non-compliant with the audit committee requirement set forth in Listed Company Manual Section 303A.07(a) as a result of Mr. Goebel’s death. The Partnership has initiated a search for a new independent director to join the Board and the Audit Committee and expects to announce a replacement as soon as reasonably practicable. Upon appointing a new member of the Audit Committee that meets the independence requirements of Section 10A of, and Rule 10A-3 under, the Securities Exchange Act of 1934, as amended, and Section 303A”

PDS Biotechnology Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s comm”

BuzzFeed, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 2, 2026, BuzzFeed, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Requirement ”). The Notice has no effect at this time on the Company’s common stock or warrants, which continue to trade on The Nasd”

My Size, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 2, 2026 By: /s/ Ronen Luzon Name: Ronen Luzon Title: Chief Executive Officer”

Iterum Therapeutics plc received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2), 5550(b)(1), 5550(b)(3)).

“February 24, 2026, Iterum Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed and continued noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market, the Company’s ordinary shares will be scheduled for delisting and will be suspended from trading on Nasdaq effective”

GRAPHJET TECHNOLOGY received a nasdaq hearing update notice regarding market value (rules 5450(b)(2), 5450(b)(3)(C)).

“February 24, 2026, Graphjet Technology, a Cayman Islands exempted company (the “ Company ”), received the decision of the Nasdaq Listing and Hearing Review Council (the “ Listing Council ”) affirming the decision of the Nasdaq Hearings Panel (the “ Panel ”) to delist the Company’s securities from The Nasdaq Stock Market LLC (“ Nasdaq ”). As previously disclosed, on November 11, 2025, the Panel determined to delist the Company’s Class A ordinary shares from Nasdaq due to deficiencies under Nasdaq Listing Rules 5450(b)(2) (market value of listed securities) and 5450(b)(3)(C) (market value of pub”

Northann Corp. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i)).

“February 24, 2026, the Company received a notification (the “Acceptance Letter”) from the NYSE American that the Plan was accepted. In the Acceptance Letter, the NYSE American granted the Company until June 8, 2027 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company is subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i) of the Company Guide during the Plan Perio”

ALLURION TECHNOLOGIES, INC. received a nyse delisting notice notice regarding other (rules 802.01B).

“March 2, 2026, Allurion Technologies, Inc., a Delaware corporation (the “Company”) announced that it received a letter (the “Delisting Notice”) from the staff of the New York Stock Exchange (the “Exchange” or “NYSE”) indicating that the Company does not meet certain of the Exchange’s continued listing standards as set forth in Section 802.01B of the NYSE Listed Company Manual that require listed companies to maintain either (i) at least $50 million in stockholders’ equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis and that the Exchange will be”

Datavault AI Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“tock Market (“Nasdaq”) notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive bu”

CIMG Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“February 23, 2026, CIMG Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1), due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 (the “Form 10-Q”), as an additional basis for the potential delisting of the Company’s securities from The Nasdaq Capital Market during the Panel’s monitor period. As previously disclosed, in a decision letter dated December 4, 2025, the Pa”

Tenon Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(b)).

“herein stating that for the 30 consecutive business day period between January 9, 2026 and February 24, 2026, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until August 24, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of the Comp”

Sphere 3D Corp. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 26, 2026, the Company received written notice from Nasdaq informing the Company that it has regained compliance with Rule 5550(a)(2) and this matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 27, 2026 SPHERE 3D CORP. By: /s/ Kurt Kalbfleisch Kurt Kalbfleisch Chief Executive Officer and Chief Financial Officer”

JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”

JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 25, 2026, Ensysce Biosciences Inc. (the “Company”) received a notice (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. Nasdaq requires that Ensysce common stock have a minimum bid price of at least $1 per share (the “Minimum Bid Price”). In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180”

Envoy Medical, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2), 5815(d)(4)(B)).

“February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026.”

reAlpha Tech Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“February 6, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) of its non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) and indicated its intention to rely on the cure period provided by Nasdaq Listing Rule 5605(c)(4)(B). Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company has a cure period to regain compliance until the earlier of the Company’s next annual meeting of stockholders and February 4, 2027. As disclosed in”

Nixxy, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 20, 2026, Nixxy, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 30 consecutive business days and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a”

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding other.

“February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. A”

Reborn Coffee, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605).

“February 19, 2026, Reborn Coffee, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Letter”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer complies with Nasdaq’s independent director, audit committee, and compensation committee requirements as set forth in Nasdaq Listing Rule 5605. However, consistent with Nasdaq Listing Rules, Nasdaq will provide the Company a cure period in order to regain compliance as follows: (i) until the earlier of the Company’s next annual stockhold”

BullFrog AI Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 19, 2026, the Company received a further notice from Nasdaq (the “February Letter”) notifying the Company that Nasdaq determined that the Company had not met the terms of the extension. Accordingly, the Company’s securities are subject to delisting unless the Company timely requests a hearing before an independent Nasdaq Hearings Panel (the “Panel”). The Company intends to timely submit a request for a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any extension period granted by the Pa”

SRx Health Solutions, Inc. received a nyse_american noncompliance notice notice regarding other (rules 301, 713).

“February 18, 2026, SRx Health Solutions, Inc. (the “Company”) received a public warning letter (the “Letter”) from the NYSE Regulation Staff of the New York Stock Exchange (the “Exchange”) notifying the Company that it failed to comply with Sections 301 and 713 of the NYSE American LLC Company Guide (the “Company Guide”). The Letter relates to the issuance of approximately 7.5 million shares (the “Subject Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), between December 31, 2025 and January 23, 2026, upon conversion of certain shares of the Company’s Ser”

CLOUDASTRUCTURE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 17, 2026, Cloudastructure, Inc., a Delaware corporation (the “ Company ”), received a written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the”

Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pr”

Abpro Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 18, 2026, Abpro Holdings, Inc. (the “Company”) received written notification from the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company not having met the terms of the Panel’s November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company’s securities will be delisted from Nasdaq, and trading will be suspended at the open of trading on February 23, 2026. The Company has 15 days after the date it received no”

Bayview Acquisition Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(D), 5810(b), 5505, 5620(a)).

“February 19, 2026, the Company received a written notice (the “Notice”) from the Staff notifying the Company that the Company has not regained compliance with the MVLS Rule, and also that the Company is not in compliance with Nasdaq Listing Rules 5450(b)(2)(C), 5810(c)(3)(D), 5810(b), and 5505 (collectively, the “MVPHS Rules”), which require the Company to maintain a minimum Market Value of Publicly Held Shares of $15.0 million, and Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires the Company to hold an annual meeting of shareholders within twelve months of the end of it”

Rain Enhancement Technologies Holdco, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“February 18, 2026, Rain Enhancement Technologies Holdco, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) which notified the Company that, for the 30 consecutive business days ended February 17, 2026, the Company’s market value of listed securities (“MVLS”) closed below the $35,000,000 threshold required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with Nasdaq listing rule 5810(c)(3)(C), the Company has 180 calendar days, or unti”

RCI HOSPITALITY HOLDINGS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 18, 2026, RCI Hospitality Holdings, Inc. (“we,” “us” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that we are not in compliance with Listing Rule 5250(c)(1) because we have failed to file our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 (the “Form 10-Q”), and because we remain delinquent in filing our Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “Form 10-K”). Under the Nasdaq Listing Rules, we have until March 31, 20”

Planet Green Holdings Corp. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“February 18, 2026, Planet Green Holdings Corp. (the “Company”) received notice (the “Notice”) from The New York Stock Exchange (the “NYSE”) that its regulatory department (the “NYSE Regulation”) had accepted the Company’s plan (the “Plan”) to regain compliance with the NYSE American LLC’s (“NYSE American”) continued listing criteria set forth in Section 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”) and granted a plan period through June 8, 2027 (the “Plan Period Deadline”). As previously reported, on December 8, 2025, the Company received a notice from NYS”

CIMG Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r”

CIMG Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 10, 2026, CIMG Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. The Company remains subject to a Hearing Panel exception to demonstrate compliance with Nasdaq Listing Rule 5250(c)(1), the Periodic Filing Requirement. On February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing”

Outlook Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accord”